DNA vaccines delivered by hybrid nanoparticles for cancer immunotherapy

DNA vaccine shows multiple advantages over conventional live-attenuated or killed vaccines, especially in prevention against chronic infectious diseases and cancer diseases, for which traditional vaccines could not offer required cellular immunity while DNA vaccine could fulfil this demand. However, the low immunogenicity of DNA vaccine limits its application in human clinical trials. This research project aims to develop a novel iron oxide-silica hybrid nanoparticle which will achieve dual functions to improve DNA vaccine efficacy – guaranteeing an excellent delivery efficiency of DNA molecules while improving innate immune responses and activation of cytotoxic T cells. The completion of this project will provide new scientific knowledge and fundamental understanding on the impact of nanoparticles on the DNA transfection and vaccine immunogenicity.

  Are you interested in a PhD at the AIBN? Click here, and start your journey today.